C-Reactive Protein Testing Market Size Worth $ 2,331.22 Million By 2032 | CAGR: 2.7%

The global C-reactive protein testing market size is expected to reach USD 2,331.22 million by 2032, according to a new study by Polaris Market Research. The report “C-Reactive Protein Testing Market Share, Size, Trends, Industry Analysis Report, By Assay Type (Immuno-turbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others); By Detection Range; By Disease Area; By End-Use; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The C-Reactive Protein (CRP) Testing Market is the market for tests and diagnostic tools to measure C-reactive protein levels in the blood. CRP is a protein produced by the liver in response to inflammation in the body, particularly in acute or chronic infections, autoimmune disorders, or tissue injury.

CRP testing is commonly used as a marker of inflammation. It is a valuable tool for diagnosing and monitoring conditions such as cardiovascular diseases, infections, rheumatoid arthritis, inflammatory bowel disease, and certain cancers.

The CRP testing market includes a range of testing methods, including high-sensitivity CRP (hs-CRP) tests, which can detect lower levels of CRP and are often used to assess the risk of cardiovascular diseases. These tests can be performed using different techniques, including enzyme-linked immunosorbent assay (ELISA), immunoturbidimetric assay, and point-of-care testing (POCT) devices.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:https://www.polarismarketresearch.com/industry-analysis/c-reactive-protein-testing-market/request-for-sample

Endometriosis is characterized by the abnormal growth of uterine tissue outside the uterus, commonly affecting the ovaries, fallopian tubes, and pelvic tissue. It can also spread beyond the pelvic area. C-reactive protein (CRP) testing plays a significant role in detecting endometriosis, as patients with the disease often exhibit higher CRP sensitivity than non-endometriosis patients. It has contributed to the growth of the market.

The market's expansion is further fueled by the increased adoption of point-of-care (POC) testing methods, which offer reliable and convenient diagnostic results. Additionally, the approval of C-reactive protein testing for diagnosing bacterial and non-bacterial infections has positively impacted market growth. The rising incidence of cardiovascular disorders has also increased the demand for CRP testing.

The COVID-19 pandemic has also had a notable impact on the market's revenue generation in 2020. Research conducted by the Mohammed VI University of Health Sciences in Morocco highlighted using CRP as an early predictor of SARS-CoV-2 infection severity. The study emphasized that CRP levels are a simple and independent factor for predicting infection severity and guiding primary care.

C-Reactive Protein Testing Market Report Highlights

• In 2023, the immunoturbidimetric assays segment accounted for the largest revenue share in the C-reactive protein testing market. This segment refers to a testing method that uses turbidity-based technology to measure the level of C-reactive protein in the blood.
• The hs (high sensitivity) CRP segment expected to witness the fastest market share during the forecast period. The increasing demand for hs-CRP testing can be attributed to its effectiveness in identifying the risk of developing cardiovascular diseases, such as coronary artery disease.
• In 2023, North America accounted for the largest market share, due to including the high prevalence of cardiovascular diseases in countries like the United States and Canada. Additionally, increased awareness about the importance of early disease detection and the availability of advanced CRP testing technologies further boosted the market growth in North America.
• The global key market players include Randox Laboratories Ltd., Laboratory Corporation of America Holdings, Quest Diagnostics, Aidian, Abaxis, Inc., BODITECH MED, INC., Abbott, Danaher, F. Getein Biotech, Inc., Roche Ltd., Merck KGaA, Siemens Healthineers AG, HORIBA, Ltd., Inc., Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Ortho Clinical Diagnostics, and Zoetis.

Polaris Market Research has segmented the C-reactive protein testing market report based on assay type, detection range, disease area, end-use, and region:

C-Reactive Protein Testing, Assay Type Outlook (Revenue - USD Million, 2019 - 2032)

• Immuno-turbidimetric Assay
• ELISA
• Clinical
• Non-clinical
• Chemiluminescence Immunoassay
• Others

C-Reactive Protein Testing, Detection Range Outlook (Revenue - USD Million, 2019 - 2032)

• hs (high sensitivity) CRP
• Conventional CRP
• cCRP

C-Reactive Protein Testing, Disease Area Outlook (Revenue - USD Million, 2019 - 2032)

• Cardiovascular Diseases
• Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Endometriosis
• Lupus
• Others

C-Reactive Protein Testing, End-Use (Revenue - USD Million, 2019 - 2032)

• Clinics
• Hospitals
• Laboratories
• Assisted Living Healthcare Facilities
• Home Care Settings
• Others

C-Reactive Protein Testing, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

• Latin America

• Argentina
• Brazil
• Mexico

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa

C-Reactive Protein Testing Market Report Scope